Minimal Functional β-Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients

por Gillard, Pieter, Hilbrands, Robert, Van de Velde, Ursule, Ling, Zhidong, Lee, Da Hae, Weets, Ilse, Gorus, Frans, De Block, Christophe, Kaufman, Leonard, Mathieu, Chantal, Pipeleers, Daniel, Keymeulen, Bart
Publicado 2013

Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

por van der Torren, Cornelis R., Verrijn Stuart, Annemarie A., Lee, DaHae, Meerding, Jenny, van de Velde, Ursule, Pipeleers, Daniel, Gillard, Pieter, Keymeulen, Bart, de Jager, Wilco, Roep, Bart O.
Publicado 2016

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

por Demeester, Simke, Keymeulen, Bart, Kaufman, Leonard, Van Dalem, Annelien, Balti, Eric V., Van de Velde, Ursule, Goubert, Patrick, Verhaeghen, Katrijn, Davidson, Howard W., Wenzlau, Janet M., Weets, Ilse, Pipeleers, Daniel G., Gorus, Frans K.
Publicado 2015

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

por Keymeulen, Bart, van Maurik, André, Inman, Dave, Oliveira, João, McLaughlin, Rene, Gittelman, Rachel M., Roep, Bart O., Gillard, Pieter, Hilbrands, Robert, Gorus, Frans, Mathieu, Chantal, Van de Velde, Ursule, Wisniacki, Nicolas, Napolitano, Antonella
Publicado 2020